Usefulness of 18F-fluoride PET/CT in Breast Cancer Patients with Osteosclerotic Bone Metastases

Nuclear Medicine and Molecular Imaging

Volumn 47, Issue 1, 2013, Pages 27-35

  Yoon, Seok Ho ^a   Kim, Ku Sang ^a   Kang, Seok Yun ^a   Song, Hee Sung ^a   Jo, Kyung Sook ^a   Choi, Bong Hoi ^b   Lee, Su Jin ^a   Yoon, Joon Kee ^a   An, Young Sil ^a  

^a Ajou University School of Medicine   (South Korea)

^b Gyeongsang National University   (South Korea)

Author keywords

Breast cancer; PET CT; Skeletal metastases

Indexed keywords

FLUORINE 18; MEDRONATE TECHNETIUM TC 99M;

ADULT; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER DIAGNOSIS; CANCER PROGNOSIS; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; MALE; OSTEOSCLEROSIS; PATIENT ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; WHOLE BODY SCINTISCANNING;

EID: 84874196114     PISSN: 18693474     EISSN: 18693482     Source Type: Journal    
DOI: 10.1007/s13139-012-0178-0     Document Type: Article

References (27)

1. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Altekruse SF, et al. SEER Cancer Statistics Review 1975-2009 (Vintage 2009 Populations). Bethesda, MD, National Cancer Institute. Available at: http://seer. cancer. gov/csr/1975_2009_pops09/. posted to the SEER web site 2012.
2. Khatcheressian JL, Wolff AC, Smith TJ, Grunfeld E, Muss HB, Vogel VG, et al. American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol. 2006; 24: 5091-7.
3. 99mTc-labeled phosphate and phosphonate agents for skeletal imaging. Semin Nucl Med. 1976; 6: 19-31.
4. Bombardieri E, Buscombe J, Lucignani G, Schober O. Advances in Nuclear Oncology: Diagnosis and Therapy. 1st ed. London: Informa Healthcare; 2007. p. 399-400.
5. Radan L, Ben-Haim S, Bar-Shalom R, Guralnik L, Israel O. The role of FDG-PET/CT in suspected recurrence of breast cancer. Cancer. 2006; 107: 2545-51.
6. 18F-Fluoride-PET in skeletal imaging. Nucl Med Mol Imaging. 2009; 43: 253-8.
7. 18F-FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol. 1998; 16: 3375-9.
8. Blau M, Nagler W, Bender MA. Fluorine-18: a new isotope for bone scanning. J Nucl Med. 1962; 3: 332-4.
9. 18F-fluoride: applying new technology to an old tracer. J Nucl Med. 2008; 49: 68-78.
10. 99mTc-methylene diphosphonate. Semin Nucl Med. 2001; 31: 28-49.
11. 99mTc-methylene diphosphonate: evaluation of renal and whole-blood kinetics. Nucl Med Commun. 2001; 22: 1037-44.
12. ICRP. ICRP publication 53: radiation dose to patients from radiopharmaceuticals. Stockholm: Elsevier; 1987. p. 17.
13. ICRP. ICRP publication 80: radiation dose to patients from radiopharmaceuticals. Stockholm: Elsevier; 1999. p. 75.
14. 18F-FDG PET/CT examinations. J Nucl Med. 2005; 46: 608-13.
15. 18F-fluoride PET/CT bone scans 1. 0. J Nucl Med. 2010; 51: 1813-20.
16. 18F-fluoride bone PET. Nucl Med Mol Imaging. 2010; 44: 55-61.
17. Hetzel M, Arslandemir C, Konig HH, Buck AK, Nussle K, Glatting G, et al. F-18 NaF PET for detection of bone metastases in lung cancer: accuracy, cost-effectiveness, and impact on patient management. J Bone Miner Res. 2003; 18: 2206-14.
18. 18F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med. 2001; 42: 1800-4.
19. 18F PET. J Nucl Med. 1999; 40: 1623-9.
20. 18F-fluoride PET/CT. J Nucl Med. 2006; 47: 287-97.
21. 18F-fluoride PET/CT for assessing bone involvement in prostate and breast cancers. Nucl Med Commun. 2011; 32: 168-76.
22. Hamaoka T, Madewell JE, Podoloff DA, Hortobagyi GN, Ueno NT. Bone imaging in metastatic breast cancer. J Clin Oncol. 2004; 22: 2942-53.
23. 18F-fluoride PET/CT. J Nucl Med. 2004; 45: 272-8.
24. 18F-fluoride measured with positron emission tomography in correlation with CT. Skeletal Radiol. 1998; 27: 72-6.
25. Theriault RL, Hortobagyi GN. Bone metastasis in breast cancer. Anticancer Drugs. 1992; 3: 455-62.
26. Du Y, Cullum I, Illidge TM, Ell PJ. Fusion of metabolic function and morphology: sequential [18F]fluorodeoxyglucose positron-emission tomography/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer. J Clin Oncol. 2007; 25(23): 3440-7.
27. Nakamoto Y, Cohade C, Tatsumi M, Hammoud D, Wahl RL. CT appearance of bone metastases detected with FDG PET as part of the same PET/CT examination. Radiology. 2005; 237: 627-34.